Radiogenomics: a key component of precision cancer medicine

被引:29
|
作者
Liu, Zaoqu [1 ,2 ,3 ]
Duan, Tian [1 ]
Zhang, Yuyuan [1 ]
Weng, Siyuan [1 ]
Xu, Hui [1 ]
Ren, Yuqing [4 ]
Zhang, Zhenyu [5 ]
Han, Xinwei [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Dept Intervent Radiol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
[2] Zhengzhou Univ, Intervent Inst, Zhengzhou 450052, Henan, Peoples R China
[3] Intervent Treatment & Clin Res Ctr Henan Prov, Zhengzhou 450052, Henan, Peoples R China
[4] Zhengzhou Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
[5] Zhengzhou Univ, Dept Neurosurg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
关键词
APPARENT DIFFUSION-COEFFICIENT; CONVOLUTIONAL NEURAL-NETWORK; METASTATIC COLORECTAL-CANCER; BREAST-CANCER; ONCOTYPE DX; ESTROGEN-RECEPTOR; COMPUTED-TOMOGRAPHY; CLEAR-CELL; MICROVASCULAR INVASION; TUMOR HETEROGENEITY;
D O I
10.1038/s41416-023-02317-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiogenomics, focusing on the relationship between genomics and imaging phenotypes, has been widely applied to address tumour heterogeneity and predict immune responsiveness and progression. It is an inevitable consequence of current trends in precision medicine, as radiogenomics costs less than traditional genetic sequencing and provides access to whole-tumour information rather than limited biopsy specimens. By providing voxel-by-voxel genetic information, radiogenomics can allow tailored therapy targeting a complete, heterogeneous tumour or set of tumours. In addition to quantifying lesion characteristics, radiogenomics can also be used to distinguish benign from malignant entities, as well as patient characteristics, to better stratify patients according to disease risk, thereby enabling more precise imaging and screening. Here, we have characterised the radiogenomic application in precision medicine using a multi-omic approach. we outline the main applications of radiogenomics in diagnosis, treatment planning and evaluations in the field of oncology with the aim of developing quantitative and personalised medicine. Finally, we discuss the challenges in the field of radiogenomics and the scope and clinical applicability of these methods.
引用
收藏
页码:741 / 753
页数:13
相关论文
共 50 条
  • [31] Precision medicine in colorectal cancer
    Aziz, Mohammad Azhar
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2019, 25 (02): : 139 - 140
  • [32] Limits to Precision Cancer Medicine
    Clark, Jeffrey W.
    Chabner, Bruce A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (01): : 96 - 96
  • [33] Nanomaterials for Cancer Precision Medicine
    Wang, Yilong
    Sun, Shuyang
    Zhang, Zhiyuan
    Shi, Donglu
    ADVANCED MATERIALS, 2018, 30 (17)
  • [34] Precision medicine in urothelial cancer
    Kitamura, Hiroshi
    ANNALS OF ONCOLOGY, 2021, 32 : S276 - S276
  • [35] Precision Medicine in Prostate Cancer
    Sakamoto, Shinichi
    Nisiho, Kazuto
    Ichikawa, Tomohiko
    ANNALS OF ONCOLOGY, 2019, 30 : 34 - 34
  • [36] Precision medicine for prostate cancer
    Galazi, Myria
    Rodriguez-Vida, Alejo
    Ng, Tony
    Mason, Malcolm
    Chowdhury, Simon
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1305 - 1315
  • [37] Cancer Precision Medicine in China
    Li, Hui
    GENOMICS PROTEOMICS & BIOINFORMATICS, 2016, 14 (05) : 325 - 328
  • [38] Precision Medicine for Pediatric Cancer
    不详
    CANCER DISCOVERY, 2015, 5 (11) : 1114 - 1114
  • [39] Precision medicine for children with cancer
    Tannock, Ian
    LANCET ONCOLOGY, 2023, 24 (09): : 952 - 954
  • [40] Cancer Precision Medicine in China
    Hui Li
    Genomics,Proteomics & Bioinformatics, 2016, (05) : 325 - 328